Height in adolescence as a risk factor for glioma subtypes: a nationwide retrospective cohort study of 2.2 million subjects.
BMI
adolescence
glioma
height
sex
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
02 08 2021
02 08 2021
Historique:
pubmed:
26
2
2021
medline:
7
8
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
Gliomas manifest in a variety of histological phenotypes with varying aggressiveness. The etiology of glioma remains largely unknown. Taller stature in adulthood has been linked with glioma risk. The aim of this study was to discern whether this association can be detected in adolescence. The cohort included 2 223 168 adolescents between the ages of 16 and 19 years. Anthropometric measurements were collected at baseline. Incident cases of glioma were extracted from the Israel National Cancer Registry over a follow-up period spanning 47 635 745 person-years. Cox proportional hazard models were used to estimate the hazard ratio (HR) for glioma and glioma subtypes according to height, body mass index (BMI), and sex. A total of 1195 patients were diagnosed with glioma during the study period. Mean (SD) age at diagnosis was 38.1 (11.7) years. Taller adolescent height (per 10-cm increase) was positively associated with the risk for glioma of any type (HR: 1.15; P = .002). The association was retained in subgroup analyses for low-grade glioma (HR: 1.17; P = .031), high-grade glioma (HR: 1.15; P = .025), oligodendroglioma (HR: 1.31; P = .015), astrocytoma (HR: 1.12; P = .049), and a category of presumed IDH-mutated glioma (HR: 1.17; P = .013). There was a trend toward a positive association between height and glioblastoma, however this had borderline statistical significance (HR: 1.15; P = .07). After stratification of the cohort by sex, height remained a risk factor for men but not for women. The previously established association between taller stature in adulthood and glioma risk can be traced back to adolescence. The magnitude of association differs by glioma subtype.
Sections du résumé
BACKGROUND
Gliomas manifest in a variety of histological phenotypes with varying aggressiveness. The etiology of glioma remains largely unknown. Taller stature in adulthood has been linked with glioma risk. The aim of this study was to discern whether this association can be detected in adolescence.
METHODS
The cohort included 2 223 168 adolescents between the ages of 16 and 19 years. Anthropometric measurements were collected at baseline. Incident cases of glioma were extracted from the Israel National Cancer Registry over a follow-up period spanning 47 635 745 person-years. Cox proportional hazard models were used to estimate the hazard ratio (HR) for glioma and glioma subtypes according to height, body mass index (BMI), and sex.
RESULTS
A total of 1195 patients were diagnosed with glioma during the study period. Mean (SD) age at diagnosis was 38.1 (11.7) years. Taller adolescent height (per 10-cm increase) was positively associated with the risk for glioma of any type (HR: 1.15; P = .002). The association was retained in subgroup analyses for low-grade glioma (HR: 1.17; P = .031), high-grade glioma (HR: 1.15; P = .025), oligodendroglioma (HR: 1.31; P = .015), astrocytoma (HR: 1.12; P = .049), and a category of presumed IDH-mutated glioma (HR: 1.17; P = .013). There was a trend toward a positive association between height and glioblastoma, however this had borderline statistical significance (HR: 1.15; P = .07). After stratification of the cohort by sex, height remained a risk factor for men but not for women.
CONCLUSIONS
The previously established association between taller stature in adulthood and glioma risk can be traced back to adolescence. The magnitude of association differs by glioma subtype.
Identifiants
pubmed: 33631004
pii: 6149925
doi: 10.1093/neuonc/noab049
pmc: PMC8328026
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1383-1392Subventions
Organisme : Israeli Cancer Association
Organisme : Israel Jacob and Lila Alther Foundation
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Neuro Oncol. 2012 Nov;14(11):1316-24
pubmed: 22952197
BMC Cancer. 2020 Aug 20;20(1):786
pubmed: 32819306
Cancer Causes Control. 2013 May;24(5):1025-31
pubmed: 23456313
Neuro Oncol. 2020 Oct 30;22(12 Suppl 2):iv1-iv96
pubmed: 33123732
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
J Neurol Sci. 2020 Jan 15;408:116552
pubmed: 31756667
J Natl Cancer Inst. 2007 Oct 17;99(20):1544-50
pubmed: 17925535
Lancet. 1998 May 9;351(9113):1393-6
pubmed: 9593409
J Epidemiol Community Health. 1996 Aug;50(4):442-6
pubmed: 8882229
Br J Cancer. 2005 Feb 28;92(4):747-50
pubmed: 15700045
Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1531-41
pubmed: 22761305
Horm Metab Res. 2003 Nov-Dec;35(11-12):694-704
pubmed: 14710348
Br J Cancer. 2019 Mar;120(6):575-576
pubmed: 30778142
Int J Cancer. 2006 Apr 1;118(7):1848-51
pubmed: 16217772
Br J Cancer. 2008 Jul 8;99(1):185-90
pubmed: 18560401
Cancer Prev Res (Phila). 2011 Sep;4(9):1385-92
pubmed: 21685234
Mol Clin Oncol. 2014 Jul;2(4):506-508
pubmed: 24940485
Br J Cancer. 2019 Mar;120(6):668-674
pubmed: 30778143
Arch Dis Child. 1975 Jan;50(1):14-26
pubmed: 164838
Neuro Oncol. 2017 Jul 1;19(7):976-985
pubmed: 28040713
Neuroepidemiology. 2000 Sep-Oct;19(5):234-44
pubmed: 10965236
J Occup Environ Med. 2005 Mar;47(3):294-8
pubmed: 15761326
Neuro Oncol. 2015 Aug;17(8):1076-85
pubmed: 25543125
J Neurooncol. 2012 Mar;107(1):207-12
pubmed: 21984115
Endocr Rev. 2005 Dec;26(7):916-43
pubmed: 16131630
Genes Dis. 2015 Mar 1;2(1):13-25
pubmed: 25984556
Cancer Res. 2009 Nov 1;69(21):8349-55
pubmed: 19808953
Am J Epidemiol. 2014 Oct 15;180(8):821-9
pubmed: 25205831
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Causes Control. 2018 Aug;29(8):707-719
pubmed: 29943102
Growth Horm IGF Res. 2000 Apr;10 Suppl A:S28-9
pubmed: 10984282
Eur J Neurol. 2011 Mar;18(3):387-95
pubmed: 20722711
Br J Cancer. 2015 Sep 1;113(5):729-37
pubmed: 26291053
Int J Epidemiol. 2012 Aug;41(4):1075-85
pubmed: 22933650